ALK and non-small cell lung carcinoma: The present study investigated how hypoxia affects the efficacy of the tyrosine kinase inhibitor crizotinib by exploring its off-target activities, rather than its established function as an anaplastic lymphoma kinase (ALK) inhibitor implicated in ALK-positive non-small cell lung cancer (NSCLC).